Reporter | Zhang Orange
Around the Spring Festival, although the mainland secondary market did not appear in the long-awaited spring sowing market, the stock market volatility intensified, and the issuance of new public funds failed to achieve a good start. However, the public offering industry is still moving continuously, on the one hand, a number of head public offerings have purchased themselves to stabilize the market, on the other hand, equity fund managers have paid close attention to the research and investigation during the holidays to reserve the strength for stock swapping.
"Red Weekly" reporter used Wind information to count the research situation before and after the Spring Festival, and on January 31 Chinese New Year's Eve, Xie Zhiyu, who has been promoted to vice president of Xingquan Fund, and Wang Peng, the star fund manager of TEDA, investigated Hemai shares by video conference. Han Chuang, a star fund manager of Dentons with outstanding performance last year, investigated Lens Technology on February 6. Jiao Wei, a Yinhua star who was once known for his preference for liquor, chose to investigate the science and technology innovation board company Xidiwei-u before the Spring Festival. In addition, at the end of the fourth quarter, the goods have surpassed Gülen, who is in the first place of Zhang Kunyue, and the two companies investigated before the holiday are ST National Medicine and Kefu Medical in the pharmaceutical sector.
The reporter learned that due to the recent sharp decline in science and technology growth track stocks represented by the Ningde era, considering the pressure of this year's performance and ranking, some fund managers who have previously pursued new energy have begun to adjust their positions and exchange shares, and the survey may also reflect the change in their thinking to some extent.
From the perspective of changes, the reporter found that it seems that the top stars are more concerned about the allocation value of new stocks that have not been listed for a long time, after experiencing this round of plunge.
The day of the "Chinese New Year's Eve"
Hemai shares attract the attention of two top streams
After Dong Cheng informally left the Xingquan Fund, Xie Zhiyu, one of the two top streams of the company, was even busier, and the total size of the four funds he is currently managing has reached 96.345 billion yuan on December 31, still ranking among the top five in the mainland. Judging from this year's survey, following the investigation of Jianghai shares and Puluo Pharmaceutical in the first half of January, Xie Zhiyu investigated Hemai shares on January 31.
As a newly listed new stock, Hemai shares enjoyed the honor of the most expensive new shares in A shares at that time, from the data point of view, Hemai shares is a high-tech enterprise with photovoltaic inverters and other power conversion equipment and electrical complete sets of equipment as the main industry. In the field of photovoltaic inverters, the company's products include micro-inverters and monitoring equipment, as well as modular inverters and other power conversion equipment designed according to the concept of micro-inverters.
From the perspective of the stock price trend of the secondary market, the stock can be described as the peak of the debut, and the intraday high of 824 yuan on the first day of listing on December 20 has become the high point so far. Of course, in the eyes of most public fund managers, the short-term ups and downs of stocks are only the result of the market sentiment game, and the performance support of fundamentals will provide a good time to open a position when the stock price falls.
Judging from the survey records of the day, Xie Zhiyu also closely focused on the company's main product micro inverter and financial status quo of the ball cannon, for example, in answering the reason why the company's sales growth was higher than the industry average, the company said that one is the photovoltaic industry, especially the distributed field itself, which is growing rapidly, and some are the development of emerging markets and the addition of new powerful customers, and the market share is also improving.
Coincidentally, Wang Peng, the star fund manager of TEDA Manulife, also investigated Hemai shares in the same way on the same day. Judging from the research records, in addition to being as concerned about the company's fundamental operation as Xie, Wang Peng seems to be more concerned about the company's prospects for the U.S. market. In this regard, the company seems to be full of confidence: "Through third-party data, the company's market share in Latin America is high, the U.S. market we entered late, the market share is gradually increasing, but compared with the global industry leader, there is still a big gap, which also shows that the U.S. market has a lot of room for growth, the company attaches great importance to the U.S. market." At present, the company's share base in the U.S. market is still relatively low, and the United States is the world's largest distributed photovoltaic market, so the company can develop a lot of space. ”
Cycle master Han Chuang investigates Lens Technology
Jiao Wei, who is well versed in consumption, investigates Xidi Micro-U
In addition to the two stars who coincided, the reporter of Red Weekly found that there are many star fund managers who seize the time to investigate around the Spring Festival, such as Han Chuang, a cyclical master of Dacheng Fund last year, who performed best in the management fund last year, and the net value growth rate of the whole year was close to 90%. But the reporter did not see Lens Technology among all the funds he managed in the quarterly heavy stocks.
As one of the leading companies in the consumer electronics sector, Lens Technology disclosed its 2021 annual performance forecast on January 28, and it is expected that the annual net profit will be 2 billion yuan to 2.4 billion yuan. The previous three quarterly reports showed that the company's net profit in the first three quarters was 3.297 billion yuan. For the whole year of 2021, the company's operating income achieved steady growth over the same period of the previous year. From the perspective of stock price trends, Lens Technology has basically walked in a straight downward channel since the end of last year.
And such a company attracts Hanchuang to investigate, perhaps also after the fall of good configuration time has appeared. Judging from the survey records, Dentons' participants asked sharp questions about the performance that did not meet expectations and whether they could maintain their leading position in the industry this year.
In this regard, Lens Technology replied that the company is confident to continue to maintain the market share of the main products and customer resource reserves to maintain the leading position in the industry, Liuyang Park is expected to add two factories to produce mobile phone back covers according to customer demand this year, the new energy vehicle business is expected to achieve higher growth, and the smart wear business is expected to achieve rapid growth.
Compared with the surprise of Han Chuangjian's indicators, another veteran star, Jiao Wei, once clearly outlined his consumption power circle with a man's stomach and a woman's face. However, the research company he chose at the same time period was Xidi Micro-U, which happened to be a new stock that was only listed on January 21 this year.
The company is one of the leading semiconductor and integrated circuit design enterprises in China, the company's main products cover DC / DC chips, super fast charge chips, lithium battery fast charge chips, port protection and signal switching chips, etc., are currently mainly used in mobile phones, notebook computers and automotive electronics, and can be widely used in wearable devices, Internet of Things devices, smart homes and other fields.
But investors in the secondary market have clearly chosen to vote with their feet, in addition to the highest intraday touch of 51.88 yuan on the first day of listing, the stock's latest closing price of 27.80 yuan is close to the waist. Judging from the research records of the day, Jiao Wei also raised multi-angle questions mainly around the company's main product chips. For example, in response to the company's future development plan, Xidi Micro-U replied that "the analog chip track is widely used, so there are many product types." The core of the development of analog chip companies lies in the size and ability of the R & D team, and the company will try to recruit professionals that match the needs of customers and carry out a global layout. ”
Gülen became the focal point of the public offering
In January, he investigated two pharmaceutical companies, ST National Medicine and Kefu Medical
Finally, of course, we should talk about Gülen, who has recently fallen into the whirlpool of public opinion, first of all, at the end of the fourth quarter, its scale of products under management has surpassed Zhang Kunyue in the first place, but behind such a position actually reflects the expectations of the people for the rise of the pharmaceutical sector that has been in a long-term decline. This week, the news about Gülen's fund being redeemed for 40 billion yuan has gone away, although the CEIBS fund has denied it, but there is indeed a possibility that the new energy stocks represented by the Ningde era have been sharply killed and redeemed.
"Red Weekly" reporter checked the four seasons of the all-market fund managed by Gülen, in the top ten heavy positions mixed by The China-Europe Alpha Hybrid and the New Starting Point of The New Starting Point of China-Europe Mingrui, CATL times and LONGi shares are the top two heavy stocks, and the proportion of shares held is as high as 8.5%. Last year, Gülen's research was also more dispersed, with more and more tendencies to penetrate into the entire field of technology growth.
From her January survey, Kefu Medical is the sub-new stock listed in October last year, the company's main business is household medical equipment, the company launched a number of products such as blood pressure monitors, nursing beds, infrared thermometers, nebulizers, wheelchairs, etc., and from the recent company's announcement, this year the company will also launch ECG monitors, ventilators, new oxygen generators, new delicate products and other products, involving a wider and wider range of products.
But perhaps also affected by the market downturn, the stock peaked on the second day of listing on the ChiNext board, reaching a maximum of 95 yuan in the intraday, while its latest closing price on February 10 was only 70.77 yuan. Judging from the main financial data of the past five years, the company is not inferior to mindray medical and Yuyue medical companies that belong to the same track.
Judging from the survey records of the day, Gülen actually asked in-depth questions around the fundamentals of the company. For example, in answering what are the company's key research and development areas in the future, Kefu Medical said that the company has established 3 research institutes this year, and through diversified cooperation with domestic and foreign research institutions and think tanks, it is committed to the exploration and research of rehabilitation medicine, vital signs, biosensing and other application fields and product types. The research direction of the Institute of Medical Electronics and Rehabilitation Medicine covers hearing, rehabilitation medicine, respiratory support and life information detection; the research direction of the Institute of Biosensing and Innovative Materials covers in vitro diagnostic product series, intelligent wearable ECG monitoring series, high-end medical biological materials, killing infection control materials and health protection nursing materials, etc.; Shenzhen Research Institute mainly focuses on the innovative research and development and production of continuous blood glucose monitoring systems and other products.
In addition, only a day apart, Gülen also investigated ST National Medicine in the form of video conference with several colleagues, and at that time, the company happened to be in the epidemic due to the suspension penalty of the emergency, which led to Dai Xing, and at that time, the company also participated in the company's research with Zhang Kun, a brother of the public offering.
After the holiday market changes, whether these target stocks will be taken into the arms of the above stars, the reporter of Red Weekly will continue to pay attention to this!
(The individual stocks mentioned in the article are only examples and are not recommended for trading.) ）